Background Ozanimod, a selective sphingosine-1-phosphate receptor modulator, is under
investigation for the treatment of inflammatory bowel disease. Methods We conducted a …

Abstract Background and Aims Oral small-molecule drugs [SMDs] are expanding the
therapeutic landscape for inflammatory bowel disease [IBD]. This systematic review and …

Background The clinical impact of histological remission on short-and long-term clinical
outcomes in patients with inflammatory bowel disease (IBD) is not well established. We …

Background and Aims The use of artificial intelligence (AI) during colonoscopy is attracting
attention as an endoscopist-independent tool to predict histologic disease activity of …

The main therapeutic goal of ulcerative colitis (UC) is to induce and maintain remission to
prevent long-term disease progression. Treat-to-target strategies, first introduced by the …

Background and Aims A composite endoscopic‐histologic remission is increasingly
explored as an important endpoint in ulcerative colitis (UC). We investigated combined …

Objectives Complete endoscopic healing, defined as Mayo endoscopic score (MES)= 0, is
an optimal target in the treatment of ulcerative colitis (UC). However, some patients with …

Background Deep remission in patients with UC has relied on initial achievement of
biochemical, endoscopic, and/or histological remission. We evaluated persistent …

Background and Aims Image-enhanced endoscopy has attracted attention as a method for
detecting inflammation and predicting outcomes in patients with ulcerative colitis (UC); …

Introduction Treatment goals for ulcerative colitis (UC) are evolving from the achievement of
clinical remission to more rigorous goals defined by endoscopic and histologic healing …